AEZS - Aeterna Zentaris pivotal growth hormone deficiency trial sees recruitment delays

Aeterna Zentaris (NASDAQ:AEZS) said that enrollment of a phase 3 trial of macimorelin in childhood-onset growth hormone deficiency is delayed due to ongoing impacts from COVID-19 and the situation between Ukraine and Russia. The company said that recruitment of the AEZS-130-P02 trial "may now continue until later into 2023" adding that it is discussing the potential impact this will have on costs and timelines with partner Novo Nordisk (NVO). Aeterna Zentaris (AEZS) said it planned to enroll 25% of its participants in Ukraine and Russia. The company noted that the first clinical sites in the U.S. and Europe are open for patient recruitment. Earlier in March, Aeterna Zentaris expanded a research program for development of COVID-19 and Chlamydia trachomatis vaccines.

For further details see:

Aeterna Zentaris pivotal growth hormone deficiency trial sees recruitment delays